Beijing Leadman reports losses, plans no dividend payout

Beijing Leadman Biochemistry (SZSE:300289) reported a net loss of ¥75.1 million for 2024, a significant drop from the ¥15.3 million profit in the previous year. Revenues also declined by 19.79%, settling at ¥370.2 million, primarily due to the impact of centralized procurement policies on in-vitro diagnostics (IVD). The company's board of directors has proposed no dividend payout for the year to strengthen the company's financial position.